Neuroendocrine neoplasms (NENs) represent a diverse group of tumors arising from neuroendocrine cells. Current World Health Organization (WHO) classification is based on tumor differentiation and grade defined by mitotic rate and/or Ki-67 index to determine prognosis and treatment options. However, some NENs do not meet WHO pathology criteria due to morphologic heterogeneity and this leads to management challenges. WHO defines poorly differentiated NENs of the gastrointestinal tract as having morphologically large or small cell features with marked elevation of Ki-67. We present a unique clinical case that does not fit either growth pattern and also has heterogeneity with a well-differentiated component. This case report and literature review highlights the current limitations of the WHO classification of small bowel NENs and the subsequent challenges in management decisions for the patients.
Introduction
The small bowel is the most common location of neuroendocrine neoplasms (NENs) [1, 2] . The majority of small bowel NENs are found in the ileum and typically represent welldifferentiated low-grade (G1) histopathologic type, whereas poorly differentiated high-grade (G3) type is a quite rare finding [1, [3] [4] [5] [6] [7] . Despite the favorable prognosis in G1 histology, approximately 48% of patients with ileum NENs present with distant disease at diagnosis and 14-17% have peritoneal carcinomatosis (PC) [1, 2, [8] [9] [10] .
Currently, the treatment of advanced ileum NENs varies from surgical options, liver-directed therapy, everolimus and somatostatin analogues for G1-G2 well-differentiated neuroendocrine tumors (NETs), to systemic chemotherapy for G3 poorly differentiated neuroendocrine carcinomas (NECs) [11, 12] . Therefore, the grade and differentiation of a tumor in accordance with the current World Health Organization (WHO) classification is an important step for clinical decision making in these patients [5, 7] . However, several studies have shown that gastroenteropancreatic (GEP) NENs can demonstrate heterogeneity in their proliferative rate/grade between the primary site and metastases [13, 14] . This heterogeneity leads to challenges in diagnosis and appropriate treatment options.
In this report, we present a rare case of metastatic heterogeneous ileum NEC, accompanied by a literature review.
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final biopsy histopathology revealing a well-differentiated G1 NET with Ki-67 < 3% and mitotic rate of < 1 per 10 high-power fields (HPF). Preoperative computed tomography (CT) revealed a mesenteric mass measuring 2.1 × 1.8 × 3.1 cm ( Fig. 1 ) and a single right hepatic lobe lesion measuring 1.1 × 1.0 cm. Gallium-68 (Ga-68) DOTATATE positron emission tomography-magnetic resonance imaging (PET-MRI) described a 1.9 × 2.8 cm lesion in the small bowel, a 2.2 × 2.1 cm mesenteric nodule, one small liver lesion and several peritoneal lesions with active tracer uptake ( Fig. 2a-d ). The patient complained of frequent bowel movements daily during previous 6 months. A 24-h urine 5-hydroxyindoleacetic acid (5-HIAA) level was elevated to 10.6 mg. Other laboratory results were within normal limits. Somatostatin analog therapy was initiated due to diarrhea and elevated 5-HIAA. The case was discussed in multidisciplinary tumor board and the patient underwent cytoreductive surgery (CRS). The primary tumor site was the terminal ileum with five small liver metastases as well as extensive peritoneal involvement. The peritoneal cancer index was 26 and a complete cytoreduction was achieved (CC-0).
Postoperative pathology reported a heterogeneous poorly differentiated G3 NEC ( Fig. 3a, b ) with perineural invasion (Fig. 4 ), regional lymph node metastases, liver and peritoneal involvement. The Ki-67 index varied within the tumor, ranging from 3% to 25% ( Fig. 5a , b) and up to 19 mitotic figures per 10 HPF ( Fig. 6 ). Features were not consistent with either small or large cell type histology. Molecular testing did not yield any targeted mutations or immunotherapy markers. The patient is currently undergoing treatment with somatostatin analog for her functional tumor and is asymptomatic without any signs of recurrence at 6-month follow-up.
Discussion
This patient was initially diagnosed after peritoneal biopsy with a resectable metastatic G1 ileum NET. One of the current standards of care for metastatic well-differentiated G1-G2 NETs is surgical resection when feasible to achieve remission [11, 12, 15] . Surgical approach is offered to patients with liver metastases when debulking of ≥ 70% of the liver metastases is possible [16] [17] [18] . Retrospective data also state that CRS provides a survival benefit in selected patients with PC of welldifferentiated NETs origin, while the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) does not improve outcomes [10, 19] . The patient underwent extensive CRS without HIPEC and the final surgical histopathology revealed a poorly differentiated G3 NEC with several non-typical features.
There have been many attempts to establish a classification of NENs covering all tumor subtypes in an effort to clarify treatment options and prognosis. However, the creation and clinical application of NENs classification remains challenging due to significant heterogeneity of these tumors [14, 20] . The A Rare Case of Heterogeneous G3 NEC of Ileum J Med Cases. 2020;11(1):6-11 most recent updated version of WHO classification is based on cell differentiation, mitotic rate and Ki-67 index [7, 21] . It divides all GEP NENs into four groups: G1 NET, G2 NET, small cell G3 NEC and large cell G3 NEC [5, 7] . The subdivision of small and large cell G3 NECs arose from lung NECs due to similar morphology, tumor behavior and treatment response [22] [23] [24] . Although the tumor in this case had G3 NEC features, neither small nor large cell histology was identified. This is an example of how the current classification does not encompass all tumor types, making final determination and treatment direction ambiguous when these rare instances are encountered.
Tumor heterogeneity is an obstacle for proper tumor classification in a particular NENs subgroup; however, this is not a rare phenomenon in well-differentiated NETs [25] . Several previous reports showed that mitotic rate and Ki-67 index can vary within one specimen and between the primary and metastases in GEP NENs [14, 26] . Tang et al reported in their retrospective review of 31 GEP G1 NET cases that the G3 component occurred in 48% of the primary tumors and in 52% of metastatic sites [13] . In contrast, tumor heterogeneity is quite uncommon in poorly differentiated NECs which typically present with consistent Ki-67 > 20% [27] . In the present case, postoperative assessment of the primary tumor revealed a G3 NEC with Ki-67 up to 25% (Fig. 5a, b ). However, a preoperative biopsy from the metastatic lesion showed a well-differentiated G1 NET with Ki-67 < 3% and mitotic rate of < 1 per 10 HPF. Therefore, it might be reasonable to consider a biopsy of different metastatic sites, but this is not always feasible [13, 25] . Without surgical exploration, it can be difficult to identify the primary tumor, therefore serial imaging can help determine if the tumor biology is concordant with the pathology results.
The clinical decisions in heterogeneous tumors are difficult as they cannot be based only on tumor grade. Expression of somatostatin receptors (SRs) status, which defines the efficacy of treatment with somatostatin analogs and peptide receptor radionuclide therapy, might be helpful in the management of this group of patients. Historically, high expression of SRs is a common diagnostic indicator of well-differentiated G1-G2 NETs, whereas poorly differentiated G3 NECs express few, if any, SRs [28, 29] . Therefore, somatostatin analogs are usually preferred for G1-G2 NETs and uncommonly administered in patients with G3 NEC [12] . However, several studies reported that up to 40-50% G3 NECs demonstrate active tracer uptake at SR-based imaging (particularly Ga-68 DOTATATE PET) [20, 30, 31] . Potentially, functional imaging can be used for prediction of response to somatostatin analog therapy based on the activity of tracer uptake [27] . In Koch et al's study, the administration of octreotide demonstrated longer progression-free survival in NET patients who had higher tracer uptake (standardized uptake value (SUV) > 20.3) on Ga-68 DOTATATE PET compared to patients with low SUV (69 and 26 weeks, respectively) [32] . In the present case, Ga-68 DO-TATATE PET-MRI also visualized several lesions with SRs ( Fig. 2a-d) with maximal SUV of 28. This allowed us to consider long-acting somatostatin analogs for treatment, despite G3 NEC pathology.
In contrast, chemotherapy has shown effectiveness in the treatment of poorly differentiated G3 NECs and no benefit in patients with G1-G2 NETs, making treatment decisions of heterogeneous tumors challenging [11, 12] . In addition, several studies indicate that the efficacy of chemotherapy varies within G3 tumors. Velayoudom-Cephise et al showed no treatment response to cisplatin-based chemotherapy in patients with well-differentiated G3 NETs in comparison with a 31% rate of response in patients with G3 NECs [20] . Another study showed worse response to chemotherapy in 15% of patients with Ki-67 < 55%, while treatment response with Ki-67 > 55% was seen in 42% [33] . The data demonstrate that the G3 group might be heterogeneous in clinical behavior and management of these tumors should not be based solely on tumor grade. In the present case, final pathology showed a poorly differentiated tumor with maximal Ki-67 of 25% and multiple foci of Ki-67 < 20%. The current clinical guidelines have not provided treatment algorithms for poorly differentiated G3 NECs tumors with a low proliferative rate [11, 12] . However, considering existing data, we assumed that the pathology characteristics of this tumor were not favorable for significant treatment response. Additional data are clearly needed to help guide the management of G3 patients with a low proliferative rate.
Molecular testing of GEP NENs can be a promising tool for choosing treatment options. For instance, pancreatic NEC patients with mutated KRAS and loss of Rb showed a much higher response rate for platinum-based chemotherapy than those with wild-type KRAS and retained Rb (100% vs. 18%, respectively) [34] . Despite a lack of data about the correlation between specific mutations and treatment response in small bowel NENs, there are some genetic mutations that can be helpful for clinical management. In a systematic review of 33 retrospective studies and eight case reports, the molecular features of GEP NECs were assessed and the presence of TP53 mutation was reported in 57-100% and loss of Rb was detected in 44-56% of cases [35] . Although there were no molecular alterations in the present case, we believe molecular testing might be useful for NETs to determine additional treatment options.
Current WHO classification is designed to guide treatment and prognosis for all NENs. Unfortunately, because of heterogeneity of these neoplasms, physicians are challenged to treat patients with tumors that cannot be defined to any of the known NEN subtypes at this current time. Considering all clinical and diagnostic data, we decided that the patient was a good candidate for long-acting octreotide for diarrhea symptom management. We hope that it will also help with tumor control, but that will be hard to determine as she has no measurable disease at this time. The patient is being closely monitored and further treatment options will be determined based on pattern and timing of recurrence.
Conclusion
This case report demonstrates the diagnostic and treatment challenges of rare heterogeneous small bowel poorly differentiated NEC. We believe that our experience can help to better clarify the challenges of the current WHO classification and clinical trial design for these patients in the future.
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